Novartis’ Xolair recommended in new global chronic urticaria guideline

Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU) , is the only therapy recommended by the guideline for patients unresponsive to antihistamines. Xolair is the only licensed treatment option for CSU, a type of chronic urticaria (CU), for patients unresponsive to antihistamines -   The guideline aims to achieve complete symptom control of patients - A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines , . Xolair is the only licensed treatment option for CSU, a type of CU, for patients unresponsive to antihistamines. CU, including CSU, is a severe disease that causes itchy, persistent hives and painful swelling. The guideline recommends Xolair as the only treatment qualified with very good efficacy and very good safety in CSU. The guideline was endorsed by key dermatologic and allergy professional medical societies around the world. Marcus Maurer, MD, Professor of Dermatology and Allergy and Director of Research at the Department of Dermatology and Allergy, Allergie-Centrum-Charité of the Charité - Universitätsmedizin in Berlin, Germany said: "I highly welcome the new guideline, as it brings greater public awareness of the disease and treatment.